Instil Bio, Inc. (TIL)
Market Cap | 65.30M |
Revenue (ttm) | n/a |
Net Income (ttm) | -123.32M |
Shares Out | 6.50M |
EPS (ttm) | -18.94 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 3,039 |
Open | 10.76 |
Previous Close | 10.30 |
Day's Range | 10.04 - 10.80 |
52-Week Range | 6.08 - 12.98 |
Beta | 1.18 |
Analysts | Buy |
Price Target | 20.33 (+102.49%) |
Earnings Date | Aug 12, 2024 |
About TIL
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for TIL stock is "Buy." The 12-month stock price forecast is $20.33, which is an increase of 102.49% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/f/g/press20-2423674.jpg)
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its f...
![](https://cdn.snapi.dev/images/v1/p/h/press4-2336430.jpg)
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its...
![](https://cdn.snapi.dev/images/v1/8/5/press2-2230252.jpg)
Instil Bio Announces Strategic Update
DALLAS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or...
![](https://cdn.snapi.dev/images/v1/2/d/press16-2184728.jpg)
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
DALLAS, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or...
![](https://cdn.snapi.dev/images/v1/o/0/press14-2155732.jpg)
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
DALLAS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies f...
![](https://cdn.snapi.dev/images/v1/8/u/press18-2141097.jpg)
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cells Presented novel preclinical data showing...
![](https://cdn.snapi.dev/images/v1/n/x/press1-2021147.jpg)
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023 Initial data from ITIL-306-202 clinical trial anticipated in 2024 ITIL-306 operational i...
![](https://cdn.snapi.dev/images/v1/h/k/press6-1948581.jpg)
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
Presented data showing that folate receptor α (FRα)-CoStAR enhanced activity of TILs against autologous NSCLC, ovarian, and renal tumors
![](https://cdn.snapi.dev/images/v1/j/r/press19-1884635.jpg)
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
ITIL-306 phase 1 study anticipated to receive CTA clearance from UK MHRA in 2H'2023 Anticipate initial clinical data from ITIL-306 phase 1 program in 2024 Cash runway beyond 2026 DALLAS, May 11, 2023 ...
![](https://cdn.snapi.dev/images/v1/h/4/press4-1820540.jpg)
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Instil confirms cash runway beyond 2026
![](https://cdn.snapi.dev/images/v1/l/s/press4-1732062.jpg)
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
Company anticipates cash resources to provide runway beyond 2026
![](https://cdn.snapi.dev/images/v1/b/i/biotech40-orafbjtuom-1713316.jpg)
7 Cheap But Risky Biotech Stocks
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.
![](https://cdn.snapi.dev/images/v1/v/d/press18-1700009.jpg)
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
Phase 1 trial of ITIL-306 in NSCLC, ovarian, and RCC re-opened to enrollment after voluntary pause
![](https://cdn.snapi.dev/images/v1/s/f/press17-1672127.jpg)
Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)
NEW YORK--(BUSINESS WIRE)--Newman Ferrara LLP announced today that the firm is conducting investigations on behalf of shareholders of Instil Bio, Inc. (NASDAQ:TIL) (“Instil” or the “Company”). The i...
![](https://cdn.snapi.dev/images/v1/c/v/press16-1667598.jpg)
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce
DALLAS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil” or the “Company”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing next-generation tumor infiltratin...
![](https://cdn.snapi.dev/images/v1/a/9/press6-1646188.jpg)
Instil Bio Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Boston, Massachusetts--(Newsfile Corp. - November 21, 2022) - Block & Leviton is investigating Instil Bio, Inc. (NASDAQ: TIL) for potential securities law violations. Investors who have lost money in ...
![](https://cdn.snapi.dev/images/v1/y/g/press2-1636129.jpg)
Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Manufacturing update on voluntary pause of DELTA-1 trial of ITIL-168 in advanced melanoma expected in Q1'23
![](https://cdn.snapi.dev/images/v1/r/r/press10-1635927.jpg)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
NEW YORK , Nov. 14, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Instil Bio, Inc. ("Instil" or the "Company") (NASDAQ: TIL). Such investors are advised to cont...
![](https://cdn.snapi.dev/images/v1/a/r/press16-1626316.jpg)
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - November 8, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I...
![](https://cdn.snapi.dev/images/v1/5/q/press1-1624372.jpg)
Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
DALLAS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies f...
![](https://cdn.snapi.dev/images/v1/2/b/press10-1622277.jpg)
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - November 7, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I...
![](https://cdn.snapi.dev/images/v1/s/t/press20-1616792.jpg)
Instil Bio Investigated by Block & Leviton for Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm
Boston, Massachusetts--(Newsfile Corp. - November 3, 2022) - Block & Leviton is investigating Instil Bio, Inc. (NASDAQ: TIL) for potential securities law violations. Investors who have lost money in t...
![](https://cdn.snapi.dev/images/v1/c/k/press3-1616542.jpg)
ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - November 3, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I...
![](https://cdn.snapi.dev/images/v1/d/d/press6-1613421.jpg)
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - November 2, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of I...
![](https://cdn.snapi.dev/images/v1/0/d/press6-1612314.jpg)
INSTIL BIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Instil Bio, Inc. on Behalf of Instil Bio Stockholders and Encourages Investors to Contact the Firm
NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C.